UK Cancer Drugs Fund Reforms Get Cautious Welcome, But More Needed
Executive Summary
NHS England has issued new guidelines on how cancer drugs will be appraised and funded in the UK, including the operation of the controversial Cancer Drugs Fund (CDF), which is being replaced by a new fund controlled by the HTA NICE from the end of July this year.
You may also be interested in...
New UK Cancer Drugs Fund Dismays Pharma, Charities
The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation. Pharma companies believe they will have to shoulder additional financial risks while patients will still not get full access to the medicines they need.
UK Cancer Drugs Fund Debuts To Muted Applause From Pharma, Charities
The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.
Eisai Says Lenvatinib Lost in UK Market Access Maze Due To NICE Inaction
Japan's Eisai is considering all options including legal action and reducing its investment in the UK to force NICE to make its potential blockbuster TKI cancer drug lenvatinib available sooner to patients with advanced thyroid cancer via the publicly-funded National Health Service.